Bone Biologics Corporation
Index- P/E- EPS (ttm)-0.53 Insider Own70.04% Shs Outstand10.35M Perf Week20.15%
Market Cap15.63M Forward P/E- EPS next Y-0.83 Insider Trans0.00% Shs Float3.13M Perf Month-28.44%
Income-1.60M PEG- EPS next Q-0.17 Inst Own0.40% Short Float1.20% Perf Quarter-24.77%
Sales- P/S- EPS this Y43.40% Inst Trans- Short Ratio0.13 Perf Half Y-58.40%
Book/sh-1.23 P/B- EPS next Y-25.80% ROA- Target Price8.00 Perf Year-97.78%
Cash/sh0.60 P/C2.70 EPS next 5Y- ROE- 52W Range1.16 - 7.12 Perf YTD-54.26%
Dividend- P/FCF- EPS past 5Y54.00% ROI- 52W High-77.39% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low38.79% ATR0.25
Employees2 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)40.85 Volatility13.71% 15.71%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.09 Prev Close1.58
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume298.01K Price1.61
Recom- SMA20-14.42% SMA50-28.29% SMA200-87.44% Volume27,302 Change1.90%
Mar-23-22 08:00AM  
Mar-18-22 07:25AM  
Mar-07-22 07:00AM  
Feb-24-22 06:00AM  
Jan-10-22 03:50PM  
Jan-05-22 08:30AM  
Nov-17-21 06:43AM  
Nov-16-21 06:49AM  
Nov-10-21 09:15AM  
Nov-02-21 07:26AM  
Oct-18-21 08:30AM  
Oct-15-21 12:00PM  
Oct-13-21 01:43PM  
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.